Beacon Pharmaceutical and their Nepal partner, Prime Care International Pvt. Ltd have jointly organized the Annual sales conference 2015 at Coxs Bazar, Bangladesh. Directors of Prime Oncology Manager of Beacon Oncology, Nepal and Hi-officia...
Beacon Pharmaceuticals limited and their Sri Lanka partner, Emerchemie has organized a seminar on targeted cancer Therapy at Hotel Cinnamon Lake Colombo. Dr. Foo Sr. consultant oncology Mount Elizabeth Hospital, Singapore was the key note s...
Daclatasvir is a new medication approved by US FDA to treat Hepatitis C. Its a research product of Bristol Myer Squibb and marketed in the brand name Daklinza.Beacon Pharmaceuticals Ltd is the 1 st global company to introduce copy of Daklin...
Beacon Pharma Prothom Alo Round Table Discussion To mark the World Cancer Day, Beacon, the first anticancer drugs manufacturing and exporting pharmaceutical company, organized a round table discussion on Cancer Treatment in Bangladesh : Cap...
Daclavir (Daclatasvir) is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is the first-ever approved HCV NS5A replication complex inhibitor, meaning it interferes with a...
Generic Revolution: Combo Blockbusters Hep C are Now at Affordable Price While every death from Hepatitis C is a human tragedy millions of people suffer chronic fatigue from the illness, often enduring decades of suffering. Considering...
